|
|||
DRUGS & SUPPLEMENTS
|
How is the drug helping you? |
Kryobulin VH® is indicated for treatment of classical hemophilia (Hemophilia A). Affected individuals frequently require therapy following minor accidents. Surgery, when required in such individuals, must be preceded by temporary corrections of the clotting abnormality. Surgical prophylaxis in severe AHF deficiency can be accomplished with an appropriately-dosed pre-surgical IV bolus of Kryobulin VH® followed by intermittent maintenance doses (see DOSAGE AND ADMINISTRATION ).
Kryobulin VH® is not effective in controlling the bleeding of patients with von Willebrand's disease.
Known hypersensitivity to mouse protein is a contraindication to Kryobulin VH®.
Kryobulin VH® is made from human blood. Products made from human plasma may contain infectious agents, such as viruses, that can cause disease. Because Kryobulin VH® is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current viral infections and inactivating and/or removing certain viruses during manufacture (see DESCRIPTION section for viral reduction measures). The manufacturing procedure for Kryobulin VH® includes processing steps designed to reduce further the risk of viral transmission. Stringent procedures utilized at plasma collection centers, plasma testing laboratories, and fractionation facilities are designed to reduce the risk of viral transmission. The primary viral reduction step of the Kryobulin VH® manufacturing process is the heat treatment of the purified, stabilized aqueous solution at 60°C for 10 hours. In addition, the purification procedure (several precipitation steps) used in the manufacture of Kryobulin VH® also provides viral reduction capacity. Despite these measures, such products may still potentially contain human pathogenic agents, including those not yet known or identified. Thus the risk of transmission of infectious agents can not be totally eliminated. Any infections thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to CSL Behring at 1-866-915-6958 (in the U.S. or Canada).
Individuals who receive infusions of blood or plasma products may develop signs and/or symptoms of some viral infections (see Information For Patients ).
Most Antihemophilic Factor concentrates contain naturally occurring blood group specific antibodies. However, the processing of Kryobulin VH® significantly reduces the presence of blood group specific antibodies in the final product. Nevertheless, when large or frequently repeated doses of product are needed, patients should be monitored by means of hematocrit and direct Coombs tests for signs of progressive anemia.
Although no hypersensitivity reactions have been observed, because Kryobulin VH® contains trace amounts of mouse protein (≤50 ng per 100 IU of AHF), the possibility exists that patients treated with Kryobulin VH® may develop hypersensitivity to the mouse proteins.
Patients should be informed of the early signs of hypersensitivity reactions including hives, generalized urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis, and should be advised to discontinue use of the concentrate and contact their physician if these symptoms occur.
Some viruses, such as parvovirus B19 or hepatitis A, are particularly difficult to remove or inactivate at this time. Parvovirus B19 most seriously affects pregnant women, or immune-compromised individuals.
Although the overwhelming number of hepatitis A and parvovirus B19 cases are community acquired, there have been reports of these infections associated with the use of some plasma-derived products. Therefore, physicians should be alert to the potential symptoms of parvovirus B19 and hepatitis A infections and inform patients under their supervision receiving plasma derived products to report potential symptoms promptly.
Symptoms of parvovirus B19 include fever, drowsiness, chills and runny nose followed two weeks later by a rash and joint pain. Evidence of hepatitis A may include several days to weeks of poor appetite, tiredness, and low-grade fever followed by nausea, vomiting and pain in the belly. Dark urine and a yellowed complexion are also common symptoms. Patients should be encouraged to consult their physicians if such symptoms occur.
Animal reproduction studies have not been conducted with Kryobulin VH®. It is also not known whether Kryobulin VH® can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Kryobulin VH® should be given to a pregnant woman only if clearly needed.
The safety and effectiveness of Kryobulin VH® for the treatment of hemophilia A has been demonstrated in 33 pediatric patients. As in adults, pediatric patients should be dosed based upon weight.
Clinical studies of Kryobulin VH® did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Dosing should be appropriate to the clinical situation.
Products of this type are known to cause allergic reactions, mild chills, nausea or stinging at the infusion site. In some cases, inhibitors of FVIII may occur.
Kryobulin VH® is for intravenous administration only. As a general rule 1 unit of AHF activity per kg will increase the circulating AHF level by 2%.10 The following formula10 provides a guide of dosage calculations for both adult and pediatric patients:
Number of AHF | = | Body weight | × | desired Factor VIII | × | 0.5 |
IU Required | increase (% normal) |
Although dosage must be individualized according to the needs of the patient (weight, severity of hemorrhage, presence of inhibitors), the following general dosages are suggested.11
(This item is individually packaged in a separate, labeled blister pack.)
Intravenous Injection
Plastic disposable syringes are recommended with Kryobulin VH® solution. The ground glass surfaces of all-glass syringes tend to stick with solutions of this type.
(This spike is supplied in the four-item Administration Components pack.)
Intravenous Injection
Plastic disposable syringes are recommended with Kryobulin VH® solution. The ground glass surfaces of all-glass syringes tend to stick with solutions of this type.
When stored at refrigerator temperature, 2-8°C (36-46°F), Kryobulin VH® is stable for the period indicated by the expiration date on its label. Within this period, Kryobulin VH® may be stored at room temperature not to exceed 25°C (77°F), for up to 6 months.
Avoid freezing which may damage container for the diluent.
Kryobulin VH® is supplied in a single dose vial with Sterile Water for Injection, USP, double-ended needle for reconstitution, vented filter spike for withdrawal, filter needle for withdrawal, winged infusion set and alcohol swabs. Factor VIII activity in IU is stated on the label of each vial.
Each product package consists of the following:
NDC Number | Component | Approximate FVIII Activity (IU) |
---|---|---|
0053-7631-02 | Carton (kit) containing one vial of Kryobulin VH® [NDC 0053-7641-01], one 2.5 mL vial of Sterile Water for Injection, USP (diluent) [NDC 0053-7653-02], one double-ended needle for reconstitution, one vented filter spike for withdrawal, one filter needle for withdrawal, one winged infusion set, and alcohol swabs. | 250 (LOW) |
0053-7632-02 | Carton (kit) containing one vial of Kryobulin VH® [NDC 0053-7642-01], one 5 mL vial of Sterile Water for Injection, USP (diluent) [NDC 0053-7653-05], one double-ended needle for reconstitution, one vented filter spike for withdrawal, one filter needle for withdrawal, one winged infusion set, and alcohol swabs. | 500 (MID) |
0053-7633-02 | Carton (kit) containing one vial of Kryobulin VH® [NDC 0053-7643-01], one 10 mL vial of Sterile Water for Injection, USP (diluent) [NDC 0053-7653-10], one double-ended needle for reconstitution, one vented filter spike for withdrawal, one filter needle for withdrawal, one winged infusion set, and alcohol swabs. | 1000 (HIGH) |
0053-7634-02 | Carton (kit) containing one vial of Kryobulin VH® [NDC 0053-7644-01], one 10 mL vial of Sterile Water for Injection, USP (diluent) [NDC 0053-7653-10], one double-ended needle for reconstitution, one vented filter spike for withdrawal, one filter needle for withdrawal, one winged infusion set, and alcohol swabs. | 1500 (SUPER HIGH) |
Hershman, R.J., Naconti, S.B., and Shulman, N.R. Prophylactic Treatment of Factor VIII Deficiency. Blood 35, (1970), p. 189.
Kasper, C.K. Dietrich, S.I. and Rapaport, S.K. Hemophilia Prophylaxis in Factor VIII Concentrate. Arch Int Med 125, (1970), p. 1004.
Biggs, R. ed. The Treatment of Hemophilia A and B and von Willebrands Disease. Oxford: Blackwell, 1978.
Fulcher, C.A., Zimmerman, T.S., Characterization of the Human Factor VIII Procoagulant Protein With A Heterologous Precipitating Antibody. Proc Natl Acad Sci 79 (1982), pp. 1648-1652.
Levine, P.H., Factor VIII C Purified from Plasma Via Monoclonal Antibodies Human Studies. Semin Hematol 25 (2 Suppl. 1), 1988, pp. 38-41.
Manufactured by:
CSL Behring LLC
Kankakee, IL 60901 USA
US License No. 1767
Revised February, 2014
12810-08
Depending on the reaction of the Kryobulin VH after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Kryobulin VH not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.
Is Kryobulin VH addictive or habit forming?Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.
Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.
There are no reviews yet. Be the first to write one! |
The information was verified by Dr. Rachana Salvi, MD Pharmacology